Pretransplant cryptococcosis and outcome after liver transplantation.
The posttransplant outcomes and optimal management of patients with end-stage liver disease who develop cryptococcosis prior to transplantation have not been defined. We discuss these issues in the context of successful liver transplantation and pretransplant cryptococcal disease. Our report suggests that liver transplantation may be cautiously considered under the umbrella of fluconazole therapy in patients with end-stage liver disease and pretransplant cryptococcosis, provided that disease control is achieved with adequate treatment before transplantation.
Sifri
Costi D
CD
University of Virginia, Charlottesville, VA, USA.
Sun
Hsin-Yun
HY
Cacciarelli
Thomas V
TV
Wispelwey
Brian
B
Pruett
Timothy L
TL
Singh
Nina
N
D000935:Antifungal Agents / Q000627:therapeutic use; D003453:Cryptococcosis / Q000150:complications*; D005355:Fibrosis / Q000150:complications* / Q000628:therapy; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017093:Liver Failure / Q000150:complications* / Q000628:therapy*; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D008875:Middle Aged; D057234:Preoperative Period; D013997:Time Factors; D016896:Treatment Outcome
D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D015725:Fluconazole